Sittings · Document

MOTION FOR A RESOLUTION (D113006/03 – 2026/2838(RPS)) 2026-09-11

On the draft Commission regulation amending Annex II to Regulation (EC) No 396/2005 of the European Parliament and of the Council as regards maximum residue levels for azoxystrobin, etofenprox, fenpropidin, flupyradifurone, hexythiazox, imazalil, spinosad and tebufenozide in or on certain products

Committee on the Environment, Climate and Food Safety · Rapporteur: Christophe Clergeau, Martin Hojsík, Jutta Paulus, Anja Hazekamp

Official HTML ↗ PDF DOCX
✦ In shortFull text
✦ In short · AI summary of this text, generated 18 Sept 2026

Parliament's resolution opposes the draft Commission regulation that would raise maximum residue levels (MRLs) for flupyradifurone and other substances in certain products. It says the draft is incompatible with Regulations (EC) No 396/2005, (EC) No 178/2002 and (EC) No 1107/2009, and asks the Commission to withdraw it and submit a new one that does not change MRLs for flupyradifurone in rapeseeds. It calls on the Commission to apply the precautionary principle, speed up the review of flupyradifurone's approval and not wait until June 2029, and not to raise any MRLs for flupyradifurone while the Article 21 procedure is unfinished.

Key points

  1. Parliament opposes adoption of the draft Commission regulation, which would raise MRLs for azoxystrobin, etofenprox, fenpropidin, flupyradifurone, hexythiazox, imazalil, spinosad and tebufenozide in or on certain products.
  2. It considers the draft incompatible with Regulations (EC) No 396/2005 and (EC) No 178/2002 and with Regulation (EC) No 1107/2009, including point 3.6.4 of Annex II thereof.
  3. It calls on the Commission to apply the precautionary principle, withdraw the draft regulation and submit a new one that does not modify MRLs for flupyradifurone in rapeseeds.
  4. It asks the Commission to urgently speed up the review of flupyradifurone's approval under Article 21 of Regulation (EC) No 1107/2009 and not wait until June 2029.
  5. It calls on the Commission not to raise any MRLs for flupyradifurone while the Article 21 procedure is unfinished, including the new MRLs proposed by EFSA.
  6. It notes the draft would raise the MRL for flupyradifurone in rapeseeds from 0,3 mg/kg to 0,4 mg/kg, and that EFSA proposes increases for almonds, hazelnuts, pistachios, walnuts, strawberries and escaroles.
  7. It states flupyradifurone was approved in 2015 for 10 years and that in July 2025 the Commission extended the authorisation until June 2029, a 3,5-year extension.
  8. It cites concerns about risks to pollinators: France asked the Commission in November 2020 to prohibit sale and use, and the Netherlands notified new information in June 2020 on the wild bee species Megachile rotundata.
  9. It cites EFSA's 2022 statement that the initial risk assessment examined only honey bees and used outdated guidance, and recommended an updated assessment under the latest OECD standards.
  10. It states the Commission opened an Article 21 review in October 2022, but has not sent EFSA a mandate including the authorisation holder's latest data on oilseed rape and sugar beet seed treatment.
  11. It cites Greece, as rapporteur Member State, finding no mitigation scenario gives acceptable risk in open field use, and a literature review to 1 March 2026 showing 72 unevaluated studies, 44 on bees and bumblebees, mostly reporting toxic effects.
  12. It states the authorisation holder failed to inform Member States of new studies as required by Article 56, that Member States should withdraw authorisations under Article 44(3)(e), and that flupyradifurone is a neonicotinoid-like substance and a PFAS whose metabolite DFA is unlikely to degrade.

Who is affected

  • The Commission: asked to withdraw the draft regulation, submit a new one and speed up the approval review.
  • Member States: should withdraw authorisations where the authorisation holder fails to comply with Regulation (EC) No 1107/2009.
  • The authorisation holder: failed to inform Member States of new studies on flupyradifurone.
  • Pollinators, including solitary bees and bumblebees: face exposure from uses of flupyradifurone in crops attractive to bees.

Figures and deadlines

  • MRL for flupyradifurone in rapeseeds: from 0,3 mg/kg to 0,4 mg/kg.
  • Flupyradifurone approved in 2015 for a period of 10 years.
  • Authorisation extended in July 2025 until June 2029, a 3,5-year extension.
  • 72 studies on effects on non-target organisms unevaluated, 44 concerning bees and bumblebees.
  • Literature review up to 1 March 2026.
  • EFSA reasoned opinion approved on 24 July 2026.
  • Standing Committee opinion delivered on 19 May 2026.

Written by a language model from the full text only; every figure comes from the text and ¶ links to the paragraph it rests on. Check the text itself before relying on it.